Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

(Reuters) -Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the ...

Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has ...

Eisai and Biogen have reported data showing that the benefit of treatment with their Alzheimer's disease therapy Leqembi appears to build over time, with no increase in safety risks. The results ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

Eisai (ESALY) and Biogen (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk in Mexico has approved humanized ...

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has been launched in South Korea. Leqembi received the ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...